Aileron Therapeutics, Inc. (ALRN, Financial) recently experienced a significant stock drop of 5.26%, bringing its price to $3.60 per share. The trading volume reached 40,402 shares with a turnover rate of 0.19% and a volatility of 7.79%. The company's latest financial report shows zero revenue, a net loss of $8.94 million, earnings per share of -$0.45, and a gross profit of -$4,000. The price-to-earnings ratio stands at -1.18.
Among the analysts covering Aileron Therapeutics, 100% recommend buying the stock. The biotechnology sector, where Aileron operates, saw an overall decline of 0.91%. However, other related companies, including Cero Therapeutics Holdings, Inc., Aligos Therapeutics, Inc., and Geovax Labs, Inc. exhibited significant gains. Cero Therapeutics Holdings, Inc., Revelation Biosciences, Inc., and Geovax Labs, Inc. demonstrated high trading activity with turnover rates of 869.49%, 514.00%, and 313.30%, respectively. Volatility was notable, with Cero Therapeutics Holdings, Inc. showing the highest at 132.14%.
Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on innovative therapies for cancer and other diseases. Its main product candidate, ALRN-6924, aims to protect healthy cells in cancer patients with p53 mutations from chemotherapy side effects. The company is also developing LTI-03 and LTI-01, along with preclinical candidates targeting fibrosis.
